Paper Details

  1. Home
  2. Paper Details

A Pilot Randomized, Controlled, Double-Blind Trial of Bumetanide to Treat Neonatal Seizures.

Author: , BerginAnn M, DongMin, FortunoCarmen R, HayesBreda, JensenFrances E, KrishnamoorthyKalpathy, O'ReillyDeirdre, RofebergValerie, SinghAvantika, SoulJanet S, StaleyKevin J, StoppChristian, VinksAlexander A, WypijDavid

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This randomized, controlled, multicenter trial tested the effectiveness of bumetanide added to phenobarbital for treating neonatal seizures. The study found that bumetanide resulted in an additional reduction in seizure burden over phenobarbital without increased serious adverse effects.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: In the absence of controlled trials, treatment of neonatal seizures has changed minimally despite poor drug efficacy. We tested bumetanide added to phenobarbital to treat neonatal seizures in the first trial to include a standard-therapy control group. METHODS: A randomized, double-blind...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/33201535

データ提供：米国国立医学図書館（NLM）

Neonatal Seizures: Navigating a Desert of Uncertainty

Neonatal seizures are a serious medical concern, posing significant challenges for physicians and families. Imagine navigating a vast and unforgiving desert, where the path to treatment is often unclear. This research explores the potential of bumetanide as a treatment option for neonatal seizures, seeking a new oasis in the desert of uncertainty.

Searching for a Healing Oasis

This randomized, controlled, double-blind trial investigates the effectiveness of bumetanide in treating neonatal seizures. The study aimed to determine if bumetanide, when added to phenobarbital, could reduce seizure burden in neonates. The researchers set out to find a more effective and safe treatment, much like searching for a life-giving oasis in a desolate desert.

A Glimpse of Hope in the Desert

The findings suggest that bumetanide, when combined with phenobarbital, may lead to a significant reduction in seizure burden. This is like finding a spring of water in the desert, offering a glimmer of hope in the face of adversity. The study highlights the potential of bumetanide as a valuable addition to the treatment of neonatal seizures, though further research is needed to confirm its efficacy.

Dr. Camel's Conclusion

This research offers a beacon of hope for families dealing with neonatal seizures. While further research is needed to fully understand the benefits and risks of bumetanide, this study provides a promising starting point for exploring new treatments for this challenging condition. This research reminds us that even in the most desolate deserts of medical uncertainty, there is always the potential for discovery and progress.
Date :
  1. Date Completed 2021-02-19
  2. Date Revised 2022-02-02
Further Info :

Pubmed ID

33201535

DOI: Digital Object Identifier

NIHMS1684126

Related Literature

Article Analysis
・Effective treatment of seizures
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.